In EAE/MS, much evidence has been obtained in support of the concept that effector Th1 (IFN-γ)- and Th17 (IL-17)-related cytokines contribute to the inflammatory response and demyelinating lesions within the CNS, while Treg- and Th2-related cytokines have been associated with anti-inflammatory effects and the improvement of symptoms [25,26]. This evidence concerns the gene IL17A and myeloid sarcoma.